Search

Your search keyword '"Elena Garralda"' showing total 214 results

Search Constraints

Start Over You searched for: Author "Elena Garralda" Remove constraint Author: "Elena Garralda" Topic business.industry Remove constraint Topic: business.industry
214 results on '"Elena Garralda"'

Search Results

1. HighFGFR1–4mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer

2. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors

3. 6P Circulating tumor DNA (ctDNA) next generation sequencing (NGS): Molecular prescreening for tailoring treatment in clinical trials

4. Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study

5. Unmasking New Promises: Expanding the Antigen Landscape For Antibody–Drug Conjugates

6. 516 Peripheral and tumoral immune activity in the expansion part of the first-in-human DuoBody®-PD-L1×4–1BB (GEN1046) trial

7. 504 A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced stage solid tumors (Acronym: GDFATHER)

8. Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials

9. Abstract CT034: Activation of the antitumor immune response of gamma9delta2 T cells in patients with solid or hematologic malignancies with ICT01, a first-in-class, monoclonal antibody targeting butyrophilin 3A: The EVICTION study

10. Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal

11. A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors

12. Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer

13. Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study

14. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW) : a multi-cohort, open-label, registrational, phase 1/2 study

15. 558TiP Phase I study of effector-function enhanced monoclonal antibody (mAb), SEA-TGT, in advanced malignancies

16. 461P Molecular tumor profiling and matched molecular targeted treatment in metastatic young-onset colorectal cancer (YOCR)

18. 1025TiP SOLTI-1904: Efficacy of spartalizumab across multiple cancer-types in patients with PD1-high mRNA expressing tumors defined by a single and pre-specified cutoff (ACROPOLI)

19. SO-29 Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive gastrointestinal cancer: An expanded dataset

20. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

21. 387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies

22. 807 A multicenter open-label phase I/lb study of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors

23. 408 Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors

24. 316 EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A

25. Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

26. The Interface Between Physical and Mental Health Problems and Medical Help Seeking in Children and Adolescents: A Research Perspective

27. Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials

28. Caring for patients with cancer in the COVID-19 era

29. Development of Pharmacodynamic Biomarkers for Phase I Trials

30. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers

31. First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

32. RNF43- and NOTCH1-Mutated Chemotherapy and Anti–EGFR-Refractory Colorectal Cancer: Should Clonality Guide Target Prioritization With Investigational Therapies?

33. 503 Clinical activity of ICT01, an anti-BTN3A-targeted, γ9δ2-activating mAb, alone and in combination with pembrolizumab in patients with advanced/refractory solid tumors: EVICTION trial

34. 520 Preliminary biomarker and pharmacodynamic (PD) activity of the TGFβ inhibitor SAR439459, alone or in combination with cemiplimab, in a phase 1 clinical study in patients with advanced solid tumors

35. 474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress)

36. 484 Preliminary efficacy of the IL-15 superagonist SO-C101 in combination with pembrolizumab in patients with advanced/metastatic solid tumors

37. MA01.06 Phase 2 of Pro-Autophagic Drug ABTL0812 in Combination With First-Line Paclitaxel and Carboplatin in IIIb/IV Squamous NSCLC

38. MO01.38 Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion+ Non-Small-Cell Lung Cancer (NSCLC)

39. Abstract CT103: Phase I study of LHC165 ± spartalizumab (PDR001) in patients (pts) with advanced solid tumors

40. P-112 Compliance analysis of biological samples and questionnaire collection in a colorectal cancer microbiome study: The VHIO experience

41. Abstract CT217: Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors

42. Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 Gatipotuzumab (GAT) with the anti-EGFR Tomuzotuximab (TO) or Panitumumab in patients with refractory solid tumors

43. 918MO Molecular enrichment and outcomes based on ESCAT levels in metastatic salivary gland tumours (mSGT) patients (pts) treated in early clinical trials

44. 1074TiP SGNTGT-001: A phase I study of SGN-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies

45. 573P Efficacy of immunotherapy (IT) after prior immune checkpoint inhibitors (ICIs) exposure

46. 864P Phase II of ABTL0812, a pro-autophagic drug, in combination with paclitaxel and carboplatin (P/C) as first-line treatment in advanced/recurrent endometrial cancer

47. 1068P Rescue chemotherapy (CT) after immune-oncology (IO) drugs in patients (pts) with refractory solid tumours: A propensity score (PS) matched cohort study

48. 477P Genomically-matched therapy in refractory CRC according to ESCAT

49. 562P Target engagement and clinical safety of CB-103, a first-in-class small molecule inhibitor of the NOTCH transcription complex

50. 29P FGFR1-4 high mRNA expression (mRNAh) as predictive biomarker for FGFR inhibitors in breast cancer (BC)

Catalog

Books, media, physical & digital resources